

Press Release

ProStrakan Group plc

Director/PDMR Shareholding

Galashiels, UK. 7th May, 2010: ProStrakan Group plc (“the Company”) has received notification that on 5th May 2010 Dr Wilson Totten, the Company’s Chief Executive Officer, acquired an interest in a total of 44,736 ordinary shares in the Company at a price of 86 pence per share.

Following this purchase, Dr Totten, together with his connected parties, has an interest in 528,284 ordinary shares, comprising 0.26% of the issued share capital of the Company.

Andrew McLean
Company Secretary

Further enquiries:

Callum Spreng 01896 664000
Corporate Communications
ProStrakan

Jon Coles/Justine McIlroy 020 7404 5959
Brunswick Group

About ProStrakan:

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company’s development capabilities are centered in Galashiels, UK, and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

Further information about the business can be found at: www.prostrakan.com